Synact Pharma Ab · OMXSTO:SYNACT
Synact Pharma Ab — Sedermera Dagen, Copenhagen 2018
15 slides from Synact Pharma Ab's conference presentation, Mar 13, 2018
Slide 1: Synact Pharma AB: A new medicine to treat inflammatory diseases
Synact Pharma AB A new medicine to treat inflammatory diseases Jeppe Øvlesen, MBA Thomas Jonassen, MD CEO CSO Sedermera Dagen Copenhagen, March 13, 2018
Slide 2: Synact Pharma – Overview
SYNACT PHARMA – OVERVIEW • Synact Pharma AB listed at Aktietorget in July 2016 • Ticker SYNACT; Aktietorget • Introduction price at 6.40 SEK per share • Current (March 6) 14.35 SEK per Share • Marked cap (March 6) of 178.0 SEK
Slide 3: Synact Pharma – Strategy – Overview
SYNACT PHARMA – STRATEGY - OVERVIEW • Main strategy is to develop lead compound AP1189 into Phase II clinical development in inflammatory joint diseases • Investigate opportunities in additional indications with the possibility to setup development path in second indication (ACTH). • Strong IP posit
Slide 4: Synact Pharma Team
SYNACT PHARMA TEAM Jeppe Øvli Øvlesen, MBA Torbjørn Bjerke, MD CEO Chairman, Board of Directors > 15 years of CEO experience Co-founder and Chairman in TXP PHarma Investor and founding Board Member at > 25 years track record from Pharma industry as Head R&D a number of Biotech/Medtech co
Slide 5: Melanocortin Therapy – Recent Deals
MELANOCORTIN THERAPY – RECENT DEALS 2012 2013 2014 2015 2017 Action TXP Questor Merck Palatins Pharma´s Pharma´s including cortico- Recynda AP214 peptide ACHTAR gel tropin program program program products (Phase 3) Phase 2 Deal value: Deal value: Deal value: Deal value: Deal value: €105m €95m €5.7b
Slide 6: Synact Pharma - Status - Today
SYNACT PHARMA - STATUS - TODAY • AP1189 SynAct Pharma´s lead project is in clinical development for active joint disease – ie rheumatoid and psoriatic arthritis • Status from ongoing Phase 1 studies shows • Well tolerated with attractive safety profile • Promising pharmacokinetics profile, supportin
Slide 7: Resolution of Inflammation: A New Therapeutic Frontier
RESOLUTION OF INFLAMMATION: A NEW THERAPEUTIC FRONTIER AP1189 Inhibits the inflammatory response - + AP1189 Stimulates the resolution phase • Resolution therapy holds promise to correct overshooting/ongoing inflammation typical of several pathological settings. Confidential information
Slide 8: Melanocortin Derived Therapy - Current Market
MELANOCORTIN DERIVED THERAPY- CURRENT MARKED • ACTH (ACHTAR gel) is a potent anti-inflammatory compound that mediates it anti- inflammatory effects through melanocortin receptor activation • Current annual sale of around $ 1.25 Bn - Source: Mallinckrodt Pharmaceuticals Investor Briefing October 4, 2
Slide 9: Melanocortin Derived Therapy
MELANOCORTIN DERIVED THERAPY- • ACTH (ACHTAR gel) has potent anti-inflammatory effects in a variety of severe autoimmune and inflammatory disorders • Two-way mode of action: 1. Melanocortin receptor activation (non-selective) 2. Release of steroid hormones • Route of administration: subcutaneous inj
Slide 10: AP1189 - Data from Phase I
AP1189- DATA FROM PHASE I Compound present in blood 24 hours following dosing • Dosing completed in 64 healthy volunteers xxxxxxxxx (male as well as post menopausal women) • In general well tolerated up to highest dose level, where peak exposures reached > 10 times the efficacious concentrations • L
Slide 11: Market Opportunity in Active Joint Disease
MARKTET OPPORTUNITY IN ACTIVE JOINT DISEASE • PsA and RA patients present with comparable clinical symptoms and respond to similar treatment modalities, despite different etiologies of disease • Both the RA and PsA treatment markets are dominated by high priced biologics providing feasibility for no
Slide 12: AP1189 – Positioning in Active Joint Disease
AP1189 – POSITIONING IN ACTIVE JOINT DISEASE • Patients with active inflammatory joint disease are currently treated with Methotrexate (MTX) • Around 40% of these patients have an inadequate response to MTX • Next line compounds are expensive and often associated with unwanted side effects • Even am
Slide 13: AP1189 – Milestones and Development Overview
AP1189 – MILESTONES AND DEVELOPMENT OVERVIEW Phase I • Part 1 and 2 completed • Part 3 to be completed Q2, 2018 followed by reporting • Preparation of Phase II Clinical trial in lead indication Q2,2018 Phase II • Trial application to be filed in Q2, 2018 • Study to be initiated in Q3, 2018 • Study t
Slide 14: AP1189 Unique Selling Points
AP1189 UNIQUE SELLING POINTS AP1189 • excellent oral PK and can be developed as a once-daily tablet formulation • very well tolerated in ongoing Phase 1 clinical testing • robust efficacy in preclinical models of arthritis, IBD and peritonitis • Ongoing studies evaluate additional development opport
Slide 15: CEO, Jeppe Øvlesen contact details
CEO, Jeppe Øvlesen joo@synactpharma.com Tel.: + 45 2844 7567 CFO, Henrik Stage hs@synactpharma.com Tel.: + 45 4026 0900 www.synactpharma.com 15